Company news

Imugene Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Appendix 4E & Annual Report to shareholders

August 31, 2020

Imugene Receives Third PD1-VAXX Ethics Trial Approval

August 20, 2020

Imugene Receives Clinical Guidance from US FDA for Vaxinia

August 5, 2020

Imugene Receives Second PD1-VAXX Ethics Trial Approval

July 16, 2020

Imugene Receives Ethics Approval to Start PD1-VAXX Trial

July 13, 2020

Imugene HER-Vaxx Phase 2 Clinical Update

May 3, 2020

Imugene PD1-Vaxx Immunotherapy Update

January 27, 2020

Imugene HER-Vaxx Immunotherapy Patent Granted in US

January 13, 2020

Imugene Share Placement to raise $24.6 million

December 1, 2019

Imugene Receives $4.13 million R&D Tax Incentive

November 4, 2019

US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy

October 22, 2019

CF33 Oncolytic Virus Clinical Trial Program Update

October 20, 2019

Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO

September 30, 2019

Investor Presentation - Proposed Acquisition

July 14, 2019

New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI

July 7, 2019

Appendix 4C - Quarterly and Business Update

April 15, 2019

IMU presents new mimotope PD-1 vaccine data at AACR

April 2, 2019

IMU presents new KEY-Vaxx and B-Vaxx data at AACR

April 1, 2019

IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx

March 19, 2019

Imugene doses first patient in HER-Vaxx phase 2 trial

March 13, 2019

IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR

March 3, 2019

Pause in Trading

February 27, 2019

IMU Meets Endpoints in Phase 1b Gastric Cancer Trial

December 16, 2018

Imugene Advances to Phase 2 in Gastric Cancer Trial

November 12, 2018

Imugene Receives $1.85 million R&D Tax Incentive

November 8, 2018

Imugene commences cGMP manufacture of PD-1 cancer vaccine

September 20, 2018

Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

September 10, 2018

Appendix 4E and Audited Financial Report

August 31, 2018

PD-1 cancer vaccine development update

July 22, 2018

Imugene raises $20.1 million

June 7, 2018

Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio

June 6, 2018

Leslie Chong Appointed as Managing Director

March 27, 2018

Arginine Modulator Active in Cancer Models

February 18, 2018

Novel Anti-PD-1 Mimotope Vaccine Ready for Development

February 11, 2018

IMU Meets Investigator for Gastric Cancer Clinical Trial

February 8, 2018

Cancer vaccine shows early promise in clinical trial

February 6, 2018

Business Update - December Quarter Appendix 4C

January 28, 2018

Rights Issue Results & Shortfall Notification

December 19, 2017

Imugene raises $8.7 million

November 22, 2017

Response to ASX Price Query

October 16, 2017

IMU Receives $1.1m R&D Tax Refund

October 10, 2017

First Patient Dosing Commences of HER-Vaxx

August 30, 2017

Imugene granted Canadian patent for Her-Vaxx cancer vaccine

July 21, 2017

Appendix 4C - quarterly and Commentry Q3

April 28, 2017

IMU Raises $3.0m from Options Plan

April 6, 2017

$1.35 million Options Underwritten

March 29, 2017

Half Year Report and Accounts

February 28, 2017

Intellectual Property Strengthened Around Lead Clinical Drug

February 26, 2017

BMC Cancer journal publishes encouraging HER-Vaxx research

February 12, 2017

Imugene progresses mimotope platform

December 18, 2016

← Newer news releases · Older news releases →

Decks

The 5 newest of 54 decks. Every deck is listed under its year.